Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial

OBJECTIVES: We sought to investigate the efficacy and safety of SpikoGen®, a subunit coronavirus disease 2019 (COVID-19) vaccine composed of a recombinant severe acute respiratory syndrome coronavirus 2 spike protein with Advax-CpG55.2™ adjuvant. METHODS: This randomized, placebo-controlled, double-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabarsi, Payam, Anjidani, Nassim, Shahpari, Ramin, Mardani, Masoud, Sabzvari, Araz, Yazdani, Babak, Kafi, Hamidreza, Fallah, Newsha, Ebrahimi, Ali, Taheri, Ali, Petrovsky, Nikolai, Barati, Saghar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463077/
https://www.ncbi.nlm.nih.gov/pubmed/36096430
http://dx.doi.org/10.1016/j.cmi.2022.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463077/
https://www.ncbi.nlm.nih.gov/pubmed/36096430
http://dx.doi.org/10.1016/j.cmi.2022.09.001

Ejemplares similares